You'll hear claims that gliptins (Januvia, etc) decrease cardiovascular risk in diabetes patients

November 2011

You'll hear claims that gliptins (Januvia, etc) decrease cardiovascular risk in diabetes patients.

This is based on a new meta-analysis that suggests gliptins don't increase cardiovascular risk...and MIGHT even decrease it.

But this analysis hasn't been peer-reviewed and published.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote